TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of acute myeloid leukemia (AML) by bone marrow biopsy~  * Newly diagnosed~* Must have adequate dendritic cells and AML blasts isolated from bone marrow and/or peripheral blood~* No clinical evidence of CNS leukemia~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No clinically significant autoimmune disease~* No other active malignancy except nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 3 months since prior immunotherapy~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin for the Treatment of Neuroleptic-Induced Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Veterans 18 and older with an observable tremor judged to be caused by exposure to antipsychotics~Exclusion Criteria:~* Concomitant use of other anticonvulsants, L-Dopa, cocaine, amphetamines, or other tremorogenic agents excepting SSRIs, TCAs.~* Current suicidality, severe psychosis, inability to sign informed consent or to cooperate with study procedures.~* Current use of gabapentin or exposure to gabapentin in the past 2 years.~* Women who are pregnant, or not using adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. established diagnosis of spinal degenerative disease indicated for lumbar spine surgery,~2. patients indicated for fusion therapy,~3. patients between 18-55 years, both sexes,~4. patients able to provide written informed consent.~Exclusion Criteria:~1. previous lumbar spine surgery in the same segment of the spine, in order to achieve vertebral fusion,~2. osteoporosis,~3. diabetes mellitus,~4. pregnancy or breastfeeding,~5. women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners,~6. fertile men not using proven contraceptive measures including effective contraception method in their partner (established oral contraception, intrauterine device, ligation of the uterine tube),~7. coagulopathy,~8. malnutrition, primary biliary cirrhosis,~9. skin infection at the site of bone marrow aspiration or at the site of spinal fusion,~10. gastrostomy,~11. any significant medical condition that would compromise the safety of the patient (e.g. recent myocardial infarction, congestive heart failure, renal failure, liver failure, systemic infection, recurrent thromboembolic disease .....),~12. alcohol or drug abuse,~13. cancer (compulsory clinical oncological screening),~14. ongoing or recent (last 3 months) systemic corticosteroid or immunosuppressive therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Human AMSC (passage 3) 3P in 1.5 mL (Type: EXPERIMENTAL): Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients ( ≥18 and ≤ 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study.~Exclusion Criteria:~* history of hemostatic abnormalities~* chronic pain syndrome~* a foot deformity restricting normal foot movement~* severe liver or renal disease~* a preexisting neurologic disorder~* patient refusal to participate~* the presence of language barrier that prohibits proper communication with patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Single Shot Sciatic Nerve Block (Type: ACTIVE_COMPARATOR): Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
- Continuous Sciatic Nerve Block (Type: ACTIVE_COMPARATOR): Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-outpatients undergoing routine screening or surveillance colonoscopy for colorectal cancer and / or polyp surveillance at Hotel Dieu Hospital~Exclusion Criteria:~* patients who have undergone colonic resections~* active inflammatory bowel disease~* hereditary polyposis syndromes~* moderate to severe chronic obstructive pulmonary disease~* obstructive sleep apnea requiring continuous positive airway pressure or biphasic positive airway pressure~* neurologic diagnoses affecting ventilation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Warmed Carbon Dioxide Insufflation (Type: EXPERIMENTAL): warmed carbon dioxide insufflation used in colonoscopy
- Room Temperature Air Insufflation (Type: ACTIVE_COMPARATOR): room temperature air insufflation used in colonoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PPI's and SSRI's Therapy for the Management of NCCP

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients should have at least 3 episodes of chest pain per week in the previous 3 months. Meanwhile they should have undergone a comprehensive diagnostic evaluation by cardiologists in order to exclude a cardiac source for their chest pain. Patients recruited in the study should have either a normal coronary angiogram or lack of ischemic heart disease on exercise treadmill or stress thallium testing.~Exclusion Criteria:~The exclusion criteria will be: i) a history of thoracic, esophageal or gastric surgery, ii) primary or secondary esophageal motility disorders, iii) use of non-steroidal anti-inflammatory drugs and aspirin, iv) presence of Barrett's esophagus, erosive esophagitis, peptic stricture and duodenal or gastric ulcer on upper endoscopy, v) eosinophilic esophagitis, vi) underlying psychiatric illness, vii) pregnancy in women, viii) refusal to participate.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GERD with PPI's therapy (Type: NO_INTERVENTION): Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
- PPI's and SSRI's therapy (Type: ACTIVE_COMPARATOR): Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
- SSRI's therapy (Type: ACTIVE_COMPARATOR): Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intraventricular Drain Insertion: Comparison of Ultrasound-guided and Landmark-based Puncture of the Ventricular System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years~* Intraventricular catheter insertion or/and intraventricular pressure measurement indicated~* Written informed consent~Exclusion Criteria~* Age \< 18 years~* previous ventricular punction \< 4 weeks~* bedside puncture indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound guided arm (Type: OTHER): None
- Landmark-based arm (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: fMRI Guided TMS Enhancement of Associative Memory Networks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in English~* Right-handed~* Score at least 26 out of 30 on the Montreal Cognitive Assessment (MOCA). Healthy subjects will be matched to age, handedness, and education compared to epilepsy subjects.~* Must be able to provide informed consent.~Exclusion Criteria:~* Any history of a neurological disorder~* Chronic or progressive medical condition~* Any history of severe traumatic brain injury or skull defect~* Metal or devices in the head, including neurostimulators of metal foreign bodies~* Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.~* Any other ferromagnetic substance in the body (including tattoos, dental prosthetics, etc).~* Taking a medication which may lower the seizure threshold within the 4 weeks prior to the start of the study, including use of neuroleptic (esp. clozapine), antibiotic (penicillin, cephalosporins), and bronchodilating medications.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Subjects (Type: ACTIVE_COMPARATOR): None
- Temporal Lobe Epilepsy Patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Impact of Protocolized Management, Intensive Rehabilitation Versus Long-term Classic Rehabilitation of Dyslexic Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children from 8 to 12 years old,~* Living in and around 50 kilometers from Besançon.~* Diagnosis of dyslexia according to the DSM-V or CIM-10 requirements.~* Consent form signed by the parental authority and the child,~* Affiliation to a social security system.~Exclusion Criteria:~* Mother's medical history of pregnancy or delivery complications,~* Patients's medical history of neurological infectious, vascular or tumoral events,~* Patient's medical history of intellectual deficiency,~* Patients's medical history of visual or hearing disorders,~* Patient's medical history of psychiatric disorders (especially diagnosis of Attention Deficit / Hyperactivity Disorders (AD/HD)),~* legal incapacity,~* limited cooperation suspected by the investigator.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- intensive arm (Type: EXPERIMENTAL): The children included in this arm will receive two weeks of daily care during which two daily speech therapy sessions of one hour each will be performed. This will be done between M2 and M4 of inclusion in order to avoid potential measurement bias. These sessions will be carried out by a state-qualified speech therapist employed at the CRRF of Bregille. They will guide the intensive rehabilitation of dyslexic children by focusing the exercises on their main difficulties.
- classic arm or gold standard (Type: ACTIVE_COMPARATOR): The speech therapy session will be provided only by private practitioners, with a weekly consultation of 30 minutes. The private speech therapist who initially referred the patient for inclusion in the research protocol will be responsible for his or her classic rehabilitation. The therapy will continue during the 6 months of research.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-op Treatment With Hyaluronic Acid Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients in post-op stage of treatment for meniscal tears or chondropathy/DJD~* Over 40 years of age~* A daily knee pain above 20mm on a 100mm visual analogue scale~Exclusion Criteria:~* Previous recipient of viscosupplementation injections~* Had rheumatoid arthritis or other inflammatory arthritis~* Had intra-articular steroid injections within the previous 2 months~* Invasive knee procedures within the past 6 months~* Contraindications to hyaluronate (an allergy)~* Medications that could interfere with the planned interventions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Viscosupplementation (Type: EXPERIMENTAL): Hyaluronic acid injection
- Saline injection (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient of the Wills Eye Institute Retina service, including all Mid-Atlantic Retina offices~2. Volunteer patients age 18 years and older~3. Healthy enough to participate in the study~4. Willing and able to consent to participation in the study~5. History of pars plan vitrectomy for symptomatic epiretinal membrane at least 3 months prior to study enrollment date~6. BCVA of 20/40 or worse~7. CMT of at least 400 micrometers with or without cystoid macular edema on SD-OCT~8. Prior treatment with topical NSAIDs without resolution of macular thickening or visual acuity improvement~Exclusion Criteria:~1. Advanced glaucoma (cup-disc ratio of 0.8 or greater)~2. History of glaucoma filtering or tube shunt implant surgery~3. Steroid responsive intraocular hypertension~4. Diabetic retinopathy~5. History of uveitis~6. Use of systemic or intraocular corticosteroids~7. Active or suspected ocular or periocular infections~8. Other confounding intraocular pathology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- 0.7mg dexamethasone intravitreal implant (Type: EXPERIMENTAL): Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Endomina Diverticulum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic medio or epiphrenic diverticulum.~2. Age between 18-80 years;~3. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;~4. Must be able to understand and be willing to provide written informed consent;~5. Must live within 75 km of the treatment site;~Exclusion Criteria:~1. Achalasia and any other esophageal motility disorders.~2. Severe esophagitis~3. Gastro-duodenal ulcer~4. Severe renal, hepatic, pulmonary disease or cancer;~5. GI stenosis or obstruction;~6. Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;~7. Anticoagulant therapy;~8. Currently participating in other study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the oral cavity, paranasal sinuses, nasopharynx, larynx, hypopharynx, or oropharynx~  * Medically or surgically inoperable disease or patient refuses surgery~ * Recurrent disease~* Previously irradiated disease meeting the following criteria:~  * Prior radiotherapy completed \> 6 months from re-irradiation~ * Prior radiotherapy in the region of the study cancer that would result in overlap of radiation therapy fields~ * Majority of the recurrent tumor volume (\> 50%) received prior radiotherapy dose of 30-75 Gy~* No distant metastatic disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 60 days after completion of study treatment~* No prior allergic reaction to study drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior surgical resection of the recurrent primary tumor and/or regional lymphatics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: EXPERIMENTAL): Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Investigator determines the subject can, and subject agrees to, adhere to the trial requirements for the length of the trial including self-administration (by subject or trained caregiver) of the study drug~* Subject completed the End-of-Study Visit in SPIMM-202~Exclusion Criteria:~* Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all trial requirements~* Subject has received any investigational compound (excluding elamipretide) and/or has participated in another interventional clinical trial within 30 days prior to the SPIMM-203 Baseline Visit (excluding SPIMM-202) or is concurrently enrolled in any non-interventional research of any type judged to be scientifically or medically incompatible with the trial as deemed by the Investigator in consultation with the Sponsor~* Subject experienced an adverse reaction attributed to study drug resulting in permanent discontinuation of study drug in the SPIMM-202 trial.~* Female subjects who are pregnant, planning to become pregnant, or lactating~* Subject has undergone an in-patient hospitalization within the 1 month prior to the SPIMM-203 Baseline Visit

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- elamipretide (Type: EXPERIMENTAL): Open-label once daily subcutaneous injection of 40mg elamipretide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy